RESUMO
Advances in laboratory and information technologies are transforming public health microbiology. High-throughput genome sequencing and bioinformatics are enhancing our ability to investigate and control outbreaks, detect emerging infectious diseases, develop vaccines, and combat antimicrobial resistance, all with increased accuracy, timeliness, and efficiency. The Advanced Molecular Detection (AMD) initiative has allowed the Centers for Disease Control and Prevention (CDC) to provide leadership and coordination in integrating new technologies into routine practice throughout the U.S. public health laboratory system. Collaboration and partnerships are the key to navigating this transition and to leveraging the next generation of methods and tools most effectively for public health.
Assuntos
Técnicas Microbiológicas/métodos , Técnicas de Diagnóstico Molecular/métodos , Administração em Saúde Pública/métodos , Humanos , Estados UnidosRESUMO
In the USA, infectious diseases continue to exact a substantial toll on health and health-care resources. Endemic diseases such as chronic hepatitis, HIV, and other sexually transmitted infections affect millions of individuals and widen health disparities. Additional concerns include health-care-associated and foodborne infections--both of which have been targets of broad prevention efforts, with success in some areas, yet major challenges remain. Although substantial progress in reduction of the burden of vaccine-preventable diseases has been made, continued cases and outbreaks of these diseases persist, driven by various contributing factors. Worldwide, emerging and reemerging infections continue to challenge prevention and control strategies while the growing problem of antimicrobial resistance needs urgent action. An important priority for control of infectious disease is to ensure that scientific and technological advances in molecular diagnostics and bioinformatics are well integrated into public health. Broad and diverse partnerships across governments, health care, academia, and industry, and with the public, are essential to effectively reduce the burden of infectious diseases.
Assuntos
Controle de Doenças Transmissíveis , Doenças Transmissíveis/epidemiologia , Saúde Pública , Animais , Controle de Doenças Transmissíveis/métodos , Vetores de Doenças , Resistência Microbiana a Medicamentos , Infecções por HIV/epidemiologia , Infecções por HIV/prevenção & controle , Hepatite Crônica/epidemiologia , Hepatite Crônica/prevenção & controle , Humanos , Incidência , Prevalência , Saúde Pública/normas , Saúde Pública/tendências , Infecções Sexualmente Transmissíveis/epidemiologia , Infecções Sexualmente Transmissíveis/prevenção & controle , Tuberculose/epidemiologia , Tuberculose/prevenção & controle , Estados Unidos/epidemiologia , Vacinação , Zoonoses/epidemiologia , Zoonoses/prevenção & controleAssuntos
Surtos de Doenças , Meningite Fúngica/epidemiologia , Administração em Saúde Pública , Anti-Inflamatórios/administração & dosagem , Centers for Disease Control and Prevention, U.S. , Comunicação , Contaminação de Medicamentos , Humanos , Meningite Fúngica/etiologia , Meningite Fúngica/prevenção & controle , Metilprednisolona/administração & dosagem , Metilprednisolona/análogos & derivados , Acetato de Metilprednisolona , Setor Privado , Administração em Saúde Pública/normas , Administração em Saúde Pública/tendências , Setor Público , Estados Unidos/epidemiologiaRESUMO
Rodents are the principal hosts of Sin Nombre virus, 4 other hantaviruses known to cause hantavirus pulmonary syndrome in North America, and the 3 North American arenaviruses. Serum samples from 757 persons who had worked with rodents in North America and handled neotomine or sigmodontine rodents were tested for antibodies against Sin Nombre virus, Whitewater Arroyo virus, Guanarito virus, and lymphocytic choriomeningitis virus. Antibodies against Sin Nombre virus were found in 4 persons, against Whitewater Arroyo virus or Guanarito virus in 2 persons, and against lymphocytic choriomeningitis virus in none. These results suggest that risk for infection with hantaviruses or arenaviruses usually is low in persons whose occupations entail close physical contact with neotomine or sigmodontine rodents in North America.
Assuntos
Anticorpos Antivirais/sangue , Arenavirus/imunologia , Síndrome Pulmonar por Hantavirus/epidemiologia , Exposição Ocupacional/efeitos adversos , Orthohantavírus/imunologia , Sigmodontinae/virologia , Animais , Síndrome Pulmonar por Hantavirus/virologia , Humanos , Incidência , América do Norte/epidemiologia , Saúde Ocupacional , Ocupações , Medição de Risco , Inquéritos e QuestionáriosRESUMO
In response to the emergence of severe acute respiratory syndrome (SARS), the United States established national surveillance using a sensitive case definition incorporating clinical, epidemiologic, and laboratory criteria. Of 1,460 unexplained respiratory illnesses reported by state and local health departments to the Centers for Disease Control and Prevention from March 17 to July 30, 2003, a total of 398 (27%) met clinical and epidemiologic SARS case criteria. Of these, 72 (18%) were probable cases with radiographic evidence of pneumonia. Eight (2%) were laboratory-confirmed SARS-coronavirus (SARS-CoV) infections, 206 (52%) were SARS-CoV negative, and 184 (46%) had undetermined SARS-CoV status because of missing convalescent-phase serum specimens. Thirty-one percent (124/398) of case-patients were hospitalized; none died. Travel was the most common epidemiologic link (329/398, 83%), and mainland China was the affected area most commonly visited. One case of possible household transmission was reported, and no laboratory-confirmed infections occurred among healthcare workers. Successes and limitations of this emergency surveillance can guide preparations for future outbreaks of SARS or respiratory diseases of unknown etiology.
Assuntos
Surtos de Doenças , Vigilância da População/métodos , Síndrome Respiratória Aguda Grave/epidemiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Sequência de Bases , Centers for Disease Control and Prevention, U.S. , Criança , Pré-Escolar , DNA Viral/genética , Diagnóstico Diferencial , Emergências , Feminino , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Saúde Pública , Infecções Respiratórias/diagnóstico , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave/genética , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave/isolamento & purificação , Síndrome Respiratória Aguda Grave/diagnóstico , Síndrome Respiratória Aguda Grave/transmissão , Estados Unidos/epidemiologiaRESUMO
On October 15, 2001, a U.S. Senate staff member opened an envelope containing Bacillus anthracis spores. Chemoprophylaxis was promptly initiated and nasal swabs obtained for all persons in the immediate area. An epidemiologic investigation was conducted to define exposure areas and identify persons who should receive prolonged chemoprophylaxis, based on their exposure risk. Persons immediately exposed to B. anthracis spores were interviewed; records were reviewed to identify additional persons in this area. Persons with positive nasal swabs had repeat swabs and serial serologic evaluation to measure antibodies to B. anthracis protective antigen (anti-PA). A total of 625 persons were identified as requiring prolonged chemoprophylaxis; 28 had positive nasal swabs. Repeat nasal swabs were negative at 7 days; none had developed anti-PA antibodies by 42 days after exposure. Early nasal swab testing is a useful epidemiologic tool to assess risk of exposure to aerosolized B. anthracis. Early, wide chemoprophylaxis may have averted an outbreak of anthrax in this population.
Assuntos
Antraz/epidemiologia , Bacillus anthracis/isolamento & purificação , Bioterrorismo , Saúde Pública/métodos , Antraz/diagnóstico , Antraz/tratamento farmacológico , Antraz/prevenção & controle , Antibioticoprofilaxia , Centers for Disease Control and Prevention, U.S./organização & administração , District of Columbia , Exposição Ambiental , Contaminação de Equipamentos , Humanos , Exposição por Inalação , Mucosa Nasal/microbiologia , Nasofaringe/microbiologia , Fatores de Risco , Estados Unidos , Local de TrabalhoRESUMO
In October 2001, four cases of inhalational anthrax occurred in workers in a Washington, D.C., mail facility that processed envelopes containing Bacillus anthracis spores. We reviewed the envelopes' paths and obtained exposure histories and nasal swab cultures from postal workers. Environmental sampling was performed. A sample of employees was assessed for antibody concentrations to B. anthracis protective antigen. Case-patients worked on nonoverlapping shifts throughout the facility, suggesting multiple aerosolization events. Environmental sampling showed diffuse contamination of the facility. Potential workplace exposures were similar for the case-patients and the sample of workers. All nasal swab cultures and serum antibody tests were negative. Available tools could not identify subgroups of employees at higher risk for exposure or disease. Prophylaxis was necessary for all employees. To protect postal workers against bioterrorism, measures to reduce the risk of occupational exposure are necessary.